The Record

The Orders Library

Name: The COVID Project Orders Library
Creator: The COVID Project

13,511 instruments indexed by The COVID Project: the orders of the fifty States and the District, forty metros, the federal layer and the agencies; the standing duties; the organizers' notices; the legal authorities. Filter by kind, State, limitation type, quarter and more; open the exhibit; download what you find.

Double quotes make a phrase ("stay at home"). An exhibit ID (TX-004) opens its record first.

The COVID Projectcovidproject.com/library

Filters:Collection: Other federal health agencies Primary source read Clear all

87 instruments · showing 26–50

Sort Per page

Exhibit	Instrument	Issuer	Jurisdiction	Issued	Quarters	Limitations	Grade
Ex. AGY-FED-HEALTH-OTHER-051	Emergency Use Authorization: Ventilators, anesthesia gas machines modified for use as ventilators, positive pressure breathing devices modified for use as ventilators, ventilator tubing connectors and ventilator accessories (Mar. 24, 2020)Letter of Authorization to Manufacturers and Other Stakeholders: Ventilators	Denise M. Hinton, Chief Scientist, FDA	United States (federal); Food and Drug AdministrationFederal	Mar. 24, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-011	DEA-DC-018 (DEA067), Dear Registrant letter granting an exception to separate State registration for practitioners dispensing in additional States during the COVID-19 emergencyDEA State Reciprocity (final) (Signed)	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 25, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Telework mandateHealth care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-131	Notice, Process for Making Available Guidance Documents Related to Coronavirus Disease 2019, 85 Fed. Reg. 16949 (Mar. 25, 2020)Process for Making Available Guidance Documents Related to Coronavirus Disease 2019	Food and Drug Administration, HHS	United States (federal); Food and Drug AdministrationFederal	Mar. 25, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Other	Primary source read
Ex. AGY-FED-HEALTH-OTHER-045	Guidance for Industry: Temporary Policy Regarding Nutrition Labeling of Certain Packaged Food During the COVID-19 Public Health Emergency (Mar. 26, 2020)Temporary Policy Regarding Nutrition Labeling of Certain Packaged Food During the COVID-19 Public Health Emergency	Food and Drug Administration, CFSAN	United States (federal); Food and Drug Administration, Center for Food Safety and Applied NutritionFederal	Mar. 26, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Context (guidance or announcement)Supply chainOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-075	Statement from BOP Director on the BOP response to the COVID-19 pandemic (Mar. 26, 2020) (Phase Four measures: screening, quarantine of new admissions, modified operations)Statement from BOP Director: BOP response to COVID-19 pandemic	Michael Carvajal, Director, Federal Bureau of Prisons	United States (federal); Federal Bureau of PrisonsFederal	Mar. 26, 2020	2020 Q2	Context (guidance or announcement)Gathering capWorkplace rulesQuarantine and isolation	Primary source read
Ex. AGY-FED-HEALTH-OTHER-081	Memorandum for Director of Bureau of Prisons, Prioritization of Home Confinement As Appropriate in Response to COVID-19 Pandemic (Mar. 26, 2020)Prioritization of Home Confinement As Appropriate in Response to COVID-19 Pandemic	William P. Barr, Attorney General	United States (federal); Department of Justice, Office of the Attorney GeneralFederal	Mar. 26, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Other	Primary source read
Ex. AGY-FED-HEALTH-OTHER-013	DEA-DC-021 (DEA073), letter to practitioner registrants and pharmacists announcing temporary exceptions for oral schedule II prescriptions in emergency situations during the COVID-19 emergencyOral CII for regular CII script (Final)	Drug Enforcement Administration, Diversion Control Division	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 27, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-037	Emergency Use Authorization Declaration (drugs and biological products), 85 Fed. Reg. 18250 (Apr. 1, 2020)Emergency Use Authorization Declaration	Alex M. Azar II, Secretary of Health and Human Services	United States (federal); Department of Health and Human Services, Office of the SecretaryFederal	Mar. 27, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Emergency declarationSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-066	VA announcement of Mar. 27, 2020 releasing the VHA COVID-19 Response Plan: elective and non-emergent procedures postponed; outpatient care shifted to telehealthVA Releases COVID-19 Response Plan	Department of Veterans Affairs	United States (federal); Department of Veterans Affairs, Veterans Health AdministrationFederal	Mar. 27, 2020	2020 Q2	Context (guidance or announcement)Telework mandateHealth care orders	Primary source read
Ex. AGY-FED-HEALTH-OTHER-050	Emergency Use Authorization: Battelle Critical Care Decontamination System for decontaminating compatible N95 respirators (issued Mar. 28, 2020; reissued Jan. 21, 2021; revoked June 30, 2021)Letter of Authorization, Battelle CCDS Critical Care Decontamination System (reissued Jan. 21, 2021)	Denise M. Hinton, Chief Scientist, FDA (letter to Battelle Memorial Institute)	United States (federal); Food and Drug AdministrationFederal	Jan. 21, 2021	2020 Q22020 Q32020 Q42021 Q12021 Q2	Health care ordersSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-028	OTP Guidance for Patients Quarantined at Home with the Coronavirus (doorstep delivery protocol) (updated Mar. 30, 2020)OTP Guidance for Patients Quarantined at Home with the Coronavirus	SAMHSA, Division of Pharmacologic Therapies, Center for Substance Abuse Treatment	United States (federal); Substance Abuse and Mental Health Services AdministrationFederal	Mar. 30, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Context (guidance or announcement)Health care ordersQuarantine and isolationOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-014	DEA-DC-022 (DEA068), letter permitting DATA-waived practitioners to prescribe buprenorphine to new patients on the basis of a telephone evaluation during the COVID-19 emergencyDEA/SAMHSA Buprenorphine Telemedicine (Final)	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control Division (with SAMHSA)Federal	Mar. 31, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Telework mandateHealth care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-015	DEA-DC-023 (DEA075), How to Prescribe Controlled Substances to Patients During the COVID-19 Public Health Emergency (decision tree)How to Prescribe Controlled Substances to Patients During the COVID-19 Public Health Emergency	Drug Enforcement Administration, Diversion Control Division	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Mar. 31, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Telework mandateHealth care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-046	Guidance for Industry: Temporary Policy Regarding Nutrition Labeling of Standard Menu Items in Chain Restaurants and Similar Retail Food Establishments During the COVID-19 Public Health Emergency (Apr. 2020)Temporary Policy Regarding Nutrition Labeling of Standard Menu Items in Chain Restaurants and Similar Retail Food Establishments During the…	Food and Drug Administration, CFSAN	United States (federal); Food and Drug Administration, Center for Food Safety and Applied NutritionFederal	Apr. 1, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Context (guidance or announcement)Other	Primary source read
Ex. AGY-FED-HEALTH-OTHER-073	COVID-19 Action Plan: Phase Five (ordered Mar. 31, 2020; effective Apr. 1, 2020): inmates secured in assigned cells/quarters for 14 days; quarantine of new admissionsCOVID-19 Action Plan: Phase Five - Additional Agency-wide Actions Effective April 1	Director, Federal Bureau of Prisons	United States (federal); Federal Bureau of PrisonsFederal	Mar. 31, 2020	2020 Q2	Business closureGathering capQuarantine and isolation	Primary source read
Ex. AGY-FED-HEALTH-OTHER-002	Enforcement Discretion Under HIPAA To Allow Uses and Disclosures of Protected Health Information by Business Associates for Public Health and Health Oversight Activities in Response to COVID-19, 85 Fed. Reg. 19392 (Apr. 7, 2020)Enforcement Discretion Under HIPAA To Allow Uses and Disclosures of Protected Health Information by Business Associates for Public Health…	Roger T. Severino, Director, Office for Civil Rights, HHS	United States (federal); Department of Health and Human Services, Office for Civil RightsFederal	Apr. 2, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-082	Memorandum for Director of Bureau of Prisons, Increasing Use of Home Confinement at Institutions Most Affected by COVID-19 (Apr. 3, 2020)Increasing Use of Home Confinement at Institutions Most Affected by COVID-19	William P. Barr, Attorney General	United States (federal); Department of Justice, Office of the Attorney GeneralFederal	Apr. 3, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Emergency declarationOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-076	Update on COVID-19 and Home Confinement (Apr. 5, 2020)Update on COVID-19 and Home Confinement: BOP continuing to aggressively screen potential inmates	Federal Bureau of Prisons	United States (federal); Federal Bureau of PrisonsFederal	Apr. 5, 2020	2020 Q2	Other	Primary source read
Ex. AGY-FED-HEALTH-OTHER-016	DEA-DC-025 (DEA078), Dear Registrant letter permitting opioid treatment programs to use the same off-site location repeatedly to deliver take-home methadone doses without separate registrationOff-site OTP delivery method (Final)	Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Apr. 7, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-003	Enforcement Discretion Regarding COVID-19 Community-Based Testing Sites (CBTS) During the COVID-19 Nationwide Public Health Emergency, 85 Fed. Reg. 29637 (May 18, 2020)Enforcement Discretion Regarding COVID-19 Community-Based Testing Sites (CBTS) During the COVID-19 Nationwide Public Health Emergency	Roger T. Severino, Director, Office for Civil Rights, HHS	United States (federal); Department of Health and Human Services, Office for Civil RightsFederal	Apr. 9, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-053	Emergency Use Authorization: Face Shields (umbrella) (issued Apr. 9, 2020; amended Apr. 13, 2020)Letter of Authorization, Face Shields (Apr. 13, 2020)	Denise M. Hinton, Chief Scientist, FDA	United States (federal); Food and Drug AdministrationFederal	Apr. 13, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersSupply chain	Primary source read
Ex. AGY-FED-HEALTH-OTHER-017	DEA-DC-027 (DEA083), letter to DEA-registered distributors and manufacturers granting an exception to the signed-delivery requirement for narcotic shipments to narcotic treatment programsDEA Dist/MNF narcotics shipments to OTP signed delivery exception (final)	William T. McDermott, Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Apr. 10, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Supply chainOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-018	DEA-DC-028 (DEA084), letter permitting DEA-registered hospitals and clinics to handle controlled substances at satellite locations under the existing registration during the COVID-19 emergencyHospital/Clinic Registration Exception (final)	William T. McDermott, Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Apr. 10, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-118	Provider Relief Fund, Acceptance of Terms and Conditions, Relief Fund Payment from Initial $30 Billion General DistributionAcceptance of Terms and Conditions - Relief Fund Payment from Initial $30 Billion General Distribution	Secretary of Health and Human Services (terms administered by HRSA)	United States (federal); Department of Health and Human Services (Health Resources and Services Administration administering the Provider Relief Fund)Federal	Apr. 10, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersOther	Primary source read
Ex. AGY-FED-HEALTH-OTHER-019	DEA-DC-029 (DEA085), letter granting a temporary exception to the five percent rule for practitioners distributing controlled substances to other registrants during the COVID-19 emergencyDEA 5 percent practitioner exception (final)	William T. McDermott, Assistant Administrator, Diversion Control Division, DEA	United States (federal); Drug Enforcement Administration, Diversion Control DivisionFederal	Apr. 13, 2020	2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3	Health care ordersSupply chainOther	Primary source read

Denise M. Hinton, Chief Scientist, FDA, Emergency Use Authorization: Ventilators, anesthesia gas machines modified for use as ventilators, positive pressure breathing devices modified for use as ventilators, ventilator tubing connectors and ventilator accessories (Mar. 24, 2020) (Ex. AGY-FED-HEALTH-OTHER-051)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA, DEA-DC-018 (DEA067), Dear Registrant letter granting an exception to separate State registration for practitioners dispensing in additional States during the COVID-19 emergency (Mar. 25, 2020) (Ex. AGY-FED-HEALTH-OTHER-011)
Food and Drug Administration, HHS, Notice, Process for Making Available Guidance Documents Related to Coronavirus Disease 2019, 85 Fed. Reg. 16949 (Mar. 25, 2020) (Ex. AGY-FED-HEALTH-OTHER-131)
Food and Drug Administration, CFSAN, Guidance for Industry: Temporary Policy Regarding Nutrition Labeling of Certain Packaged Food During the COVID-19 Public Health Emergency (Mar. 26, 2020) (Ex. AGY-FED-HEALTH-OTHER-045)
Michael Carvajal, Director, Federal Bureau of Prisons, Statement from BOP Director on the BOP response to the COVID-19 pandemic (Mar. 26, 2020) (Phase Four measures: screening, quarantine of new admissions, modified operations) (Ex. AGY-FED-HEALTH-OTHER-075)
William P. Barr, Attorney General, Memorandum for Director of Bureau of Prisons, Prioritization of Home Confinement As Appropriate in Response to COVID-19 Pandemic (Mar. 26, 2020) (Ex. AGY-FED-HEALTH-OTHER-081)
Drug Enforcement Administration, Diversion Control Division, DEA-DC-021 (DEA073), letter to practitioner registrants and pharmacists announcing temporary exceptions for oral schedule II prescriptions in emergency situations during the COVID-19 emergency (Mar. 27, 2020) (Ex. AGY-FED-HEALTH-OTHER-013)
Alex M. Azar II, Secretary of Health and Human Services, Emergency Use Authorization Declaration (drugs and biological products), 85 Fed. Reg. 18250 (Apr. 1, 2020) (Mar. 27, 2020) (Ex. AGY-FED-HEALTH-OTHER-037)
Department of Veterans Affairs, VA announcement of Mar. 27, 2020 releasing the VHA COVID-19 Response Plan: elective and non-emergent procedures postponed; outpatient care shifted to telehealth (Ex. AGY-FED-HEALTH-OTHER-066)
Denise M. Hinton, Chief Scientist, FDA (letter to Battelle Memorial Institute), Emergency Use Authorization: Battelle Critical Care Decontamination System for decontaminating compatible N95 respirators (issued Mar. 28, 2020; reissued Jan. 21, 2021; revoked June 30, 2021) (Ex. AGY-FED-HEALTH-OTHER-050)
SAMHSA, Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, OTP Guidance for Patients Quarantined at Home with the Coronavirus (doorstep delivery protocol) (updated Mar. 30, 2020) (Ex. AGY-FED-HEALTH-OTHER-028)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA, DEA-DC-022 (DEA068), letter permitting DATA-waived practitioners to prescribe buprenorphine to new patients on the basis of a telephone evaluation during the COVID-19 emergency (Mar. 31, 2020) (Ex. AGY-FED-HEALTH-OTHER-014)
Drug Enforcement Administration, Diversion Control Division, DEA-DC-023 (DEA075), How to Prescribe Controlled Substances to Patients During the COVID-19 Public Health Emergency (decision tree) (Mar. 31, 2020) (Ex. AGY-FED-HEALTH-OTHER-015)
Food and Drug Administration, CFSAN, Guidance for Industry: Temporary Policy Regarding Nutrition Labeling of Standard Menu Items in Chain Restaurants and Similar Retail Food Establishments During the COVID-19 Public Health Emergency (Apr. 2020) (Apr. 1, 2020) (Ex. AGY-FED-HEALTH-OTHER-046)
Director, Federal Bureau of Prisons, COVID-19 Action Plan: Phase Five (ordered Mar. 31, 2020; effective Apr. 1, 2020): inmates secured in assigned cells/quarters for 14 days; quarantine of new admissions (Ex. AGY-FED-HEALTH-OTHER-073)
Roger T. Severino, Director, Office for Civil Rights, HHS, Enforcement Discretion Under HIPAA To Allow Uses and Disclosures of Protected Health Information by Business Associates for Public Health and Health Oversight Activities in Response to COVID-19, 85 Fed. Reg. 19392 (Apr. 7, 2020) (Apr. 2, 2020) (Ex. AGY-FED-HEALTH-OTHER-002)
William P. Barr, Attorney General, Memorandum for Director of Bureau of Prisons, Increasing Use of Home Confinement at Institutions Most Affected by COVID-19 (Apr. 3, 2020) (Ex. AGY-FED-HEALTH-OTHER-082)
Federal Bureau of Prisons, Update on COVID-19 and Home Confinement (Apr. 5, 2020) (Ex. AGY-FED-HEALTH-OTHER-076)
Thomas W. Prevoznik, Deputy Assistant Administrator, Diversion Control Division, DEA, DEA-DC-025 (DEA078), Dear Registrant letter permitting opioid treatment programs to use the same off-site location repeatedly to deliver take-home methadone doses without separate registration (Apr. 7, 2020) (Ex. AGY-FED-HEALTH-OTHER-016)
Roger T. Severino, Director, Office for Civil Rights, HHS, Enforcement Discretion Regarding COVID-19 Community-Based Testing Sites (CBTS) During the COVID-19 Nationwide Public Health Emergency, 85 Fed. Reg. 29637 (May 18, 2020) (Apr. 9, 2020) (Ex. AGY-FED-HEALTH-OTHER-003)
Denise M. Hinton, Chief Scientist, FDA, Emergency Use Authorization: Face Shields (umbrella) (issued Apr. 9, 2020; amended Apr. 13, 2020) (Ex. AGY-FED-HEALTH-OTHER-053)
William T. McDermott, Assistant Administrator, Diversion Control Division, DEA, DEA-DC-027 (DEA083), letter to DEA-registered distributors and manufacturers granting an exception to the signed-delivery requirement for narcotic shipments to narcotic treatment programs (Apr. 10, 2020) (Ex. AGY-FED-HEALTH-OTHER-017)
William T. McDermott, Assistant Administrator, Diversion Control Division, DEA, DEA-DC-028 (DEA084), letter permitting DEA-registered hospitals and clinics to handle controlled substances at satellite locations under the existing registration during the COVID-19 emergency (Apr. 10, 2020) (Ex. AGY-FED-HEALTH-OTHER-018)
Secretary of Health and Human Services (terms administered by HRSA), Provider Relief Fund, Acceptance of Terms and Conditions, Relief Fund Payment from Initial $30 Billion General Distribution (Apr. 10, 2020) (Ex. AGY-FED-HEALTH-OTHER-118)
William T. McDermott, Assistant Administrator, Diversion Control Division, DEA, DEA-DC-029 (DEA085), letter granting a temporary exception to the five percent rule for practitioners distributing controlled substances to other registrants during the COVID-19 emergency (Apr. 13, 2020) (Ex. AGY-FED-HEALTH-OTHER-019)

The Orders Library

Results